middle.news
Noxopharm Secures First US Patent for Breakthrough Cancer Immunotherapy
8:36am on Wednesday 22nd of October, 2025 AEDT
•
Biotechnology
Read Story
Noxopharm Secures First US Patent for Breakthrough Cancer Immunotherapy
8:36am on Wednesday 22nd of October, 2025 AEDT
Key Points
First-tier US patent granted for Sofra™ technology platform
Patent protects novel immune-modulatory oligonucleotides for cancer treatment
Sofra platform’s potential extends beyond inflammation to immuno-oncology
SOF-SKN™, a first-in-class drug, advancing through clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE